---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-147869"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2021-12-09T23:59:59+00:00"
generated_at: "2026-06-28T02:29:21.202845+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Entrada reports Q3 2021 net loss $14.4M and closes $208.7M IPO

## Summary
- Net loss for Q3 2021 was $14.4M vs $7.0M in Q3 2020; R&D expense $10.5M, G&A $3.9M.
- Closed upsized IPO in November, raising $208.7M gross ($190.9M net) at $20.00 per share.
- IPO included full exercise of underwriters' option for 1.36M additional shares; total shares issued 10.44M.
- Cash position as of Sep 30, 2021 was $122.2M, excluding IPO proceeds; post-IPO cash significantly strengthened.
- Lead candidate ENTR-601-44 for DMD advancing toward initial clinical data; DM1 program entering development.

## SEC filing metadata
- accession: 0001104659-21-147869
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2021-12-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465921147869/0001104659-21-147869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465921147869/tm2134805d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-147869
- JSON: https://secwatch.observer/filing/0001104659-21-147869.json
- Plain text: https://secwatch.observer/filing/0001104659-21-147869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.